{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:18:56Z","timestamp":1786580336387,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jacbts.2016.06.007","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T16:45:14Z","timestamp":1480524314000},"page":"568-575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Circulating PCSK9 and Risk of Myocardial\u00a0Infarction"],"prefix":"10.1016","volume":"1","author":[{"given":"Lars E.","family":"Laugsand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn O.","family":"\u00c5svold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars J.","family":"Vatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Janszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl G.","family":"Platou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika E.","family":"Michelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan K.","family":"Dam\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2016.06.007_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":"Lipid lowering with PCSK9 inhibitors","volume":"11","author":"Dadu","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacbts.2016.06.007_bib2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacbts.2016.06.007_bib3","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.06.007_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10557-015-6582-9","article-title":"Update of clinical trials of anti-PCSK9 antibodies","volume":"29","author":"Wu","year":"2015","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacbts.2016.06.007_bib5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.metabol.2013.01.005","article-title":"Association of serum proprotein convertase subtilisin\/kexin type 9 with carotid intima media thickness in hypertensive subjects","volume":"62","author":"Lee","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.jacbts.2016.06.007_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.hlc.2015.10.017","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 as a predictor of carotid atherosclerosis in asymptomatic adults","volume":"25","author":"Chan","year":"2016","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacbts.2016.06.007_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2010.09.027","article-title":"Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population","volume":"213","author":"Cui","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacbts.2016.06.007_bib8","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1161\/ATVBAHA.111.240549","article-title":"Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels","volume":"32","author":"Chernogubova","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2016.06.007_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","article-title":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","volume":"62","author":"Werner","year":"2014","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jacbts.2016.06.007_bib10","doi-asserted-by":"crossref","first-page":"e2426","DOI":"10.1097\/MD.0000000000002426","article-title":"Proprotein convertase subtilisin\/kexin type 9, C-reactive protein, coronary severity, and outcomes in patients with stable coronary artery disease: a prospective observational cohort study","volume":"94","author":"Li","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacbts.2016.06.007_bib11","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating proprotein convertase subtilisin\/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors","volume":"133","author":"Leander","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2016.06.007_bib12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/eurheartj\/ehv568","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 levels and the risk of first cardiovascular events","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2016.06.007_bib13","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","article-title":"Association of proprotein convertase subtilisin\/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention","volume":"35","author":"Zhu","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2016.06.007_bib14","first-page":"19","article-title":"The Nord-Tr\u00f8ndelag Health Study 1995 -97 (HUNT 2): objectives, contents, methods and participation","volume":"13","author":"Holmen","year":"2003","journal-title":"Norsk epidemiologi"},{"key":"10.1016\/j.jacbts.2016.06.007_bib15","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1161\/CIRCULATIONAHA.111.025858","article-title":"Insomnia and the risk of acute myocardial infarction: a population study","volume":"124","author":"Laugsand","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2016.06.007_bib16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","article-title":"Myocardial infarction redefined\u2014a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction","volume":"36","author":"Alpert","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.06.007_bib17","series-title":"Modern Epidemiology","author":"Rothman","year":"2008"},{"key":"10.1016\/j.jacbts.2016.06.007_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01621459.1983.10477915","article-title":"Multiplicative models in cohort analysis","volume":"78","author":"Breslow","year":"1983","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.jacbts.2016.06.007_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbrc.2007.07.029","article-title":"Plasma PCSK9 levels correlate with cholesterol in men but not in women","volume":"361","author":"Mayne","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacbts.2016.06.007_bib20","doi-asserted-by":"crossref","first-page":"e106294","DOI":"10.1371\/journal.pone.0106294","article-title":"Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies","volume":"9","author":"Almontashiri","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2016.06.007_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000319067","article-title":"Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study","volume":"30","author":"Canoui-Poitrine","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jacbts.2016.06.007_bib22","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting\u00a0the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.06.007_bib23","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacbts.2016.06.007_bib24","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.108.817619","article-title":"Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001","volume":"119","author":"Forsdahl","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2016.06.007_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","article-title":"Clinical aspects of PCSK9","volume":"216","author":"Cariou","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacbts.2016.06.007_bib26","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arterioscl Thromb Vasc Biol"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X16300997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X16300997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:18:06Z","timestamp":1762820286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X16300997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S2452302X16300997"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2016.06.007","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating PCSK9 and Risk of Myocardial\u00a0Infarction","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2016.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}